The Trouble with ESUS: What do the studies tell us? Where do we do from here?
Kamel, Hooman
( Weill Cornell Medicine
, New York
, New York
, United States
)
Messe, Steven
( University of Pennsylvania
, Philadelphia
, Pennsylvania
, United States
)
Author Disclosures:
Hooman Kamel:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
| Steven Messe:DO NOT have relevant financial relationships